Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.

Francesco Passiglia, Marta Castiglia, Konstantinos Papadimitriou, Marta Castiglia, Francesco Passiglia, Marcin Ostrowski, Ana Dolcan, Lúcia Farracho, Tereza Ondøichová, Patrick Pauwels, Roy Remmen, Christian Rolfo, Roy Remmen

Risultato della ricerca: Articlepeer review

17 Citazioni (Scopus)

Abstract

In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.
Lingua originaleEnglish
pagine (da-a)124-133
Numero di pagine10
RivistaJournal of the American Board of Family Medicine
Volume28
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Family Practice

Fingerprint Entra nei temi di ricerca di 'Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.'. Insieme formano una fingerprint unica.

Cita questo